Opportunity Information: Apply for RFA HD 18 101
Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy (R41/R42) is a National Institutes of Health (NIH) funding opportunity designed to push forward new multipurpose prevention technologies (MPTs) that can protect adolescent girls and young women from both HIV infection and unintended pregnancy. It uses the STTR mechanism, meaning it is aimed at small businesses working in close collaboration with a research institution partner, with the expectation that strong science will be paired with a credible path toward development and eventual real-world use. The core idea behind the program is that a single product or platform that addresses both risks at once could be more practical and acceptable to users than having to rely on multiple separate prevention methods.
The opportunity focuses on innovation in two connected areas: combining active agents (for example, an HIV prevention agent together with a contraceptive agent) and designing or improving delivery systems that make those combinations workable, safe, and easier to use. The emphasis on delivery matters because adherence is often the difference between an intervention that works in a study and one that works in everyday life. The NIH is signaling that prevention tools that are simpler to follow, less burdensome, and better aligned with user preferences may lead to higher and more consistent use, particularly among younger populations. In that context, the program encourages approaches that integrate HIV prevention and pregnancy prevention into a unified modality, with the long-term goal of a viable, effective combination product that meets the needs of young women at risk.
This is a discretionary grant opportunity (Funding Instrument: Grant; Activity Category: Health, Income Security and Social Services) with CFDA number 93.865. The funding opportunity number is RFA-HD-18-101, and the original application closing date listed is 2018-01-22, with a creation date of 2017-11-22. The activity codes R41 and R42 correspond to the two-phase STTR structure: a Phase I (R41) component typically supports early feasibility and proof-of-concept work, while Phase II (R42) supports more advanced R&D aimed at strengthening the technology and moving it closer to commercialization or implementation. Even without the specific award ceiling and expected number of awards spelled out in the provided text, the framing clearly indicates NIH interest in early-to-mid stage translational development that can lead to practical prevention products.
Eligibility is limited to small businesses, consistent with the STTR program. Foreign institutions (non-U.S. entities) are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components, as defined under the NIH Grants Policy Statement, may be allowable in some cases, so applicants would need to follow the detailed eligibility and policy language in the full announcement if any aspect of the work involves foreign collaboration, sites, or resources. Overall, the opportunity is centered on accelerating inventive, combination-based prevention technologies that respond to the real-world challenge that HIV risk and unintended pregnancy often overlap for adolescent girls and young women, and that prevention options that reduce complexity for the end user may improve sustained protection.Apply for RFA HD 18 101
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy (R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865.
- This funding opportunity was created on 2017-11-22.
- Applicants must submit their applications by 2018-01-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy (R41/R42)
What is this funding opportunity?
This is a National Institutes of Health (NIH) funding opportunity titled "Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy (R41/R42)." It supports research and development aimed at creating or advancing multipurpose prevention technologies (MPTs) that can help protect adolescent girls and young women from both HIV infection and unintended pregnancy.
What is the main goal of the program?
The program is intended to push forward innovative, combination-based prevention technologies that address HIV prevention and pregnancy prevention together. The central idea is that a single integrated product or platform could be more practical and acceptable than using multiple separate prevention methods.
Who is the target population emphasized in this opportunity?
The opportunity specifically emphasizes tools designed to protect adolescent girls and young women, focusing on the overlap of HIV risk and unintended pregnancy risk in this population.
What types of innovations does NIH want to fund under this announcement?
The opportunity highlights innovation in two connected areas: (1) combining active agents (for example, an HIV prevention agent together with a contraceptive agent) and (2) designing or improving delivery systems that make those combinations workable, safe, and easier to use.
What are "multipurpose prevention technologies (MPTs)" in this context?
In this context, MPTs are prevention products or platforms intended to address more than one reproductive health risk at the same time, specifically HIV prevention and prevention of unintended pregnancy.
Why is there an emphasis on delivery systems and adherence?
The announcement underscores that adherence can be the difference between an intervention that works in a study and one that works in everyday life. NIH signals interest in prevention tools that are simpler to follow, less burdensome, and better aligned with user preferences, because that may support higher and more consistent use, particularly among younger populations.
What funding mechanism does this opportunity use?
This opportunity uses the STTR mechanism (Small Business Technology Transfer). It is aimed at small businesses working in close collaboration with a research institution partner, pairing strong science with a credible path toward development and eventual real-world use.
What do the activity codes R41 and R42 mean?
R41 and R42 reflect the two-phase STTR structure. Phase I (R41) typically supports early feasibility and proof-of-concept work. Phase II (R42) supports more advanced research and development to strengthen the technology and move it closer to commercialization or implementation.
Is this a grant or a contract?
The funding instrument listed is a grant (discretionary grant opportunity).
What is the funding opportunity number?
The funding opportunity number is RFA-HD-18-101.
What is the CFDA number for this opportunity?
The CFDA number provided is 93.865.
What is the activity category listed for this opportunity?
The activity category is Health, Income Security and Social Services.
When was this opportunity created, and what is the application closing date shown?
The creation date listed is 2017-11-22, and the original application closing date listed is 2018-01-22.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with the STTR program requirements.
Are foreign institutions eligible to apply?
No. Foreign institutions (non-U.S. entities) are not eligible to apply.
Are non-domestic components of U.S. organizations eligible to apply?
No. Non-domestic components of U.S. organizations are also not eligible to apply.
Are any foreign components allowed at all?
The information provided indicates that foreign components, as defined under the NIH Grants Policy Statement, may be allowable in some cases. If any part of the work involves foreign collaboration, sites, or resources, applicants would need to follow the detailed eligibility and policy language in the full announcement.
Does this opportunity require collaboration with a research institution?
Yes. Because it uses the STTR mechanism, it is intended for small businesses working in close collaboration with a research institution partner.
What stage of research and development is NIH aiming to support?
Based on the R41/R42 framing, NIH is signaling interest in early-to-mid stage translational development, moving from feasibility and proof-of-concept toward more advanced R&D that strengthens the technology and advances it toward eventual real-world use.
Does the provided information specify an award ceiling or the expected number of awards?
No. The provided text does not include a specific award ceiling or an expected number of awards.
What kinds of prevention approaches are encouraged?
The program encourages approaches that integrate HIV prevention and pregnancy prevention into a unified modality, with the long-term goal of a viable and effective combination product that fits the needs of young women at risk and reduces complexity for the end user.
What is the long-term outcome NIH is trying to achieve through this program?
The long-term goal described is to help advance combination-based prevention products that are viable, effective, and aligned with real-world use, particularly for adolescent girls and young women who may face overlapping risks of HIV infection and unintended pregnancy.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)
Previous opportunity: BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trials Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HD 18 101
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HD 18 101) also looked into and applied for these:
| Funding Opportunity |
|---|
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21 Clinical Trial Optional) Apply for PAR 18 214 Funding Number: PAR 18 214 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01 Clinical Trial Optional) Apply for PAR 18 215 Funding Number: PAR 18 215 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Research Education Programs (R25 Clinical Trial Optional) Apply for PAR 18 217 Funding Number: PAR 18 217 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $150,000 |
| NICHD Small Grant Program (R03 - Clinical Trial Optional) Apply for PA 18 481 Funding Number: PA 18 481 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| NICHD Research Project Grant (R01 - Clinical Trial Required) Apply for PA 18 480 Funding Number: PA 18 480 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Exploratory/Developmental Research Grant (R21 - Clinical Trial Optional) Apply for PA 18 482 Funding Number: PA 18 482 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R01 - Clinical Trial Optional) Apply for RFA HD 19 013 Funding Number: RFA HD 19 013 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Studies in Neonatal and Pediatric Resuscitation (R01 Clinical Trial Optional) Apply for PA 18 485 Funding Number: PA 18 485 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Studies in Neonatal and Pediatric Resuscitation (R03 - Clinical Trial Optional) Apply for PA 18 491 Funding Number: PA 18 491 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Non-Invasive Diagnostics to Improve Gynecologic Health (R43/R44 - Clinical Trial Optional) Apply for RFA HD 19 006 Funding Number: RFA HD 19 006 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 - Clinical Trial Optional) Apply for PAR 18 506 Funding Number: PAR 18 506 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional) Apply for PAR 18 511 Funding Number: PAR 18 511 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Human-Animal Interaction (HAI) Research (R21 - Clinical Trial Optional) Apply for PAR 18 650 Funding Number: PAR 18 650 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Human-Animal Interaction (HAI) Research (R03 - Clinical Trial Optional) Apply for PAR 18 649 Funding Number: PAR 18 649 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R03 Clinical Trial Optional) Apply for PA 18 687 Funding Number: PA 18 687 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Innovative Therapies and Tools for Screenable Disorders (R01 Clinical Trial Optional) Apply for PAR 18 689 Funding Number: PAR 18 689 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Tools for Screenable Disorders (R03 Clinical Trial Optional) Apply for PAR 18 690 Funding Number: PAR 18 690 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Innovative Therapies and Tools for Screenable Disorders (R21 Clinical Trial Optional) Apply for PAR 18 691 Funding Number: PAR 18 691 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R01 Clinical Trial Optional) Apply for PA 18 688 Funding Number: PA 18 688 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Reproductive Scientist Development Program (RSDP) (K12 Clinical Trial Not Allowed) Apply for RFA HD 18 103 Funding Number: RFA HD 18 103 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $920,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HD 18 101", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.